Adage Capital Partners
INZY

Adage Capital Partners’s Inozyme Pharma INZY Stock Holding History

Adage Capital Partners’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,160,000
Closed -$4.7M – 897
2025
Q1 		$4.7M Hold
5,160,000
– – 0.01% 709
2024
Q4 		$14.3M Sell
5,160,000
-513,629
-9% -$1.95M 0.03% 520
2024
Q3 		$29.7M Sell
5,673,629
-55,227
-1% -$287K 0.05% 347
2024
Q2 		$25.6M Buy
5,728,856
+400,000
+8% +$1.94M 0.05% 372
2024
Q1 		$40.8M Sell
5,328,856
-208,644
-4% -$1.14M 0.08% 277
2023
Q4 		$23.6M Hold
5,537,500
– – 0.05% 379
2023
Q3 		$23.3M Buy
5,537,500
+1,287,500
+30% +$6.55M 0.05% 351
2023
Q2 		$23.7M Sell
4,250,000
-15,138
-0.4% -$89.5K 0.05% 363
2023
Q1 		$24.4M Buy
4,265,138
+1,165,000
+38% +$3.08M 0.05% 367
2022
Q4 		$3.26M Buy
3,100,138
+503,466
+19% +$880K 0.01% 784
2022
Q3 		$6.96M Buy
2,596,672
+50,000
+2% +$181K 0.02% 729
2022
Q2 		$12.1M Buy
2,546,672
+800,000
+46% +$3.48M 0.03% 619
2022
Q1 		$7.14M Buy
1,746,672
+147,644
+9% +$869K 0.01% 783
2021
Q4 		$10.9M Buy
1,599,028
+131,200
+9% +$1.13M 0.02% 667
2021
Q3 		$17M Buy
1,467,828
+179,156
+14% +$2.79M 0.03% 530
2021
Q2 		$22M Buy
1,288,672
+199,000
+18% +$3.46M 0.04% 432
2021
Q1 		$21.6M Buy
1,089,672
+193,000
+22% +$4.26M 0.04% 425
2020
Q4 		$18.5M Buy
896,672
+96,672
+12% +$2.3M 0.04% 430
2020
Q3 		$21M Buy
+800,000
New +$19.9M 0.05% 363

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Adage Capital Partners's INZY Position: Q2 2025 in Review

Adage Capital Partners sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 5,160,000 shares — an estimated $4.7M sold.

Adage Capital Partners first reported a position in INZY in Q3 2020 and held it in 19 quarters. The position peaked at $40.8M in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Adage Capital Partners reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Adage Capital Partners sold 5,160,000 Inozyme Pharma shares in Q2 2025, an estimated $4.7M.
  • Adage Capital Partners first reported a position in Inozyme Pharma in Q3 2020 and held it in 19 quarters.
  • Adage Capital Partners's Inozyme Pharma position peaked at $40.8M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Adage Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.